Traditionally, manufacturers preparing to launch had three commercialization options: sell, out-license or launch on their own. However, these options may not be ideal for new oncology therapies. Similar to the way contract research organizations disrupted the market in the ’90s before becoming an industry staple, EVERSANA’s fourth commercialization option is the next phase of evolution for pharma.
EVERSANA ONCOLOGY Commercialization is the optimal solution for oncology and hematology drug manufacturers. Through our award-winning commercialization model and innovative cancer drug launch strategy, our partners optimize their investments, minimize risk and increase speed to market.
Read the latest article from EVERSANA’s experts Anne Marie Robertson, Barry Vucsko, Jordan Schell, Vanitha Sankaran, PhD, and Jordan Hayes. Learn more about how EVERSANA is advancing CAR-T therapy to community practices and the strategies to overcome associated challenges.
READ NOWA recent study examined 10 real-world pharma launches and compared them to companies that embraced this new, innovative, scalable commercialization model. The study concluded that those who launched in the traditional model overspent by 23%, without any upside on launch success. Download the white paper to see an in-depth analysis of all launches and costs.